Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M
Portfolio Pulse from Nabaparna Bhattacharya
Krystal Biotech (NASDAQ:KRYS) has sold its Rare Pediatric Disease Priority Review Voucher (PRV) for $100 million. The PRV was awarded following the FDA's accelerated approval of Vyjuvek, a treatment for dystrophic epidermolysis bullosa (DEB). The company estimates about 3,000 total DEB patients in the U.S. KRYS shares are trading higher by 0.15% to $119.58.
August 21, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The sale of the PRV for $100 million could provide a financial boost for Krystal Biotech. The FDA's approval of Vyjuvek also validates the company's research and development capabilities.
The sale of the PRV provides a significant cash inflow for Krystal Biotech, which could be used to fund further research and development or other corporate activities. The FDA's approval of Vyjuvek also demonstrates the company's ability to develop effective treatments, which could enhance its reputation and potentially lead to increased investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100